Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests

HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.